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Abstract 58 
Background: Defects in the phagocytic NADPH oxidase 2 (NOX2) function cause chronic 59 
granulomatous disease (CGD), a primary immunodeficiency characterized by dysfunctional 60 
microbicidal activity and chronic inflammation.  61 
Objective: To study the effect of chronic inflammation on the hematopoietic compartment in 62 
patients and mice with the X-linked form of CGD (X-CGD). 63 
Methods: We used immunostaining and functional analyses to study the hematopoietic 64 
compartment in CGD.  65 
Results: Analysis of bone marrow (BM) cells from X-CGD patients and mice revealed a 66 
dysregulated hematopoiesis characterized by increased numbers of hematopoietic progenitors 67 
(HPCs) at the expense of repopulating hematopoietic stem cells (HSCs). In X-CGD patients 68 
there was a clear reduction in the proportion of HSCs in BM and peripheral blood and they 69 
were also more rapidly exhausted after in vitro culture. In X-CGD mice, increased cycling of 70 
HSCs, expansion of HPCs and impaired long-term engraftment capacity were found to be 71 
associated with high concentrations of proinflammatory cytokines, including interleukin 1 72 
beta (IL-1. Treatment of wild-type mice with IL-1 induced enhanced cell cycle entry of 73 
HSCs, expansion of HPCs and defects in long-term engraftment, mimicking the effects 74 
observed in X-CGD mice. Inhibition of cytokine signaling in X-CGD mice reduced HPC 75 
numbers but had only minor effects on the repopulating ability of HSCs.   76 
Conclusions: Persistent chronic inflammation in CGD is associated with hematopoietic 77 
proliferative stress leading to a decrease in the functional activity of HSCs. Our observations 78 
have clinical implications for the development of successful autologous cell therapy 79 
approaches.  80 
81 
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Key messages:  82 
 83 
 Chronic inflammation in X-CGD is associated with dysregulated hematopoiesis and 84 
impaired hematopoietic stem cell activity.  85 
 86 
 IL-1 is increased in X-CGD and induces cycling of hematopoietic stem cells leading 87 
to a decrease in HSC function and increased numbers of hematopoietic progenitors 88 
with limited repopulating capacities.   89 
 90 
 91 
Capsule Summary  92 
Inflammation in X-CGD is associated with increased numbers of HPCs and functionally 93 
impaired HSCs as a result of increased cytokine production, including IL-1     94 
 95 
 96 
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Abbreviations  103 
BM: bone marrow 104 
CFU: colony forming unit 105 
CGD: Chronic Granulomatous Disease 106 
CMP/MEP/GMP: common myeloid progenitor/megakaryocyte-erythroid 107 
progenitor/granulocyte-macrophage progenitor 108 
CRU: competitive repopulating unit 109 
HC: healthy control 110 
HSC/HPC: hematopoietic stem cell / hematopoietic progenitor cell 111 
NADPH: nicotinamide adenine dinucleotide phosphate 112 
NOX2: NADPH oxidase 2 113 
PB: peripheral blood    114 
WT: wild type  115 
X-CGD: X-linked CGD 116 
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Introduction 118 
Chronic Granulomatous Disease (CGD) is a rare inherited primary immunodeficiency 119 
characterized by defective antimicrobicidal activity of phagocytes, resulting in increased 120 
susceptibility to recurrent and life-threatening infections.1-6 In addition, CGD patients often 121 
display augmented inflammatory responses, even in the absence of infectious agents (sterile 122 
inflammation), leading to granuloma formation and inflammatory bowel disease.7-10 123 
Approximately two thirds of all CGD patients have mutations within the X-linked CYBB gene 124 
(X-CGD), encoding the gp91phox subunit of NOX2. X-CGD mice faithfully reproduce the 125 
pathology observed in X-CGD patients.7,11 126 
CGD can be cured by allogeneic HSC transplantation, which has been particularly successful 127 
in patients with a fully HLA-matched donor in combination with reduced-intensity 128 
conditioning.12,13 Despite the use of advanced HSC transplantation protocols, cases of low 129 
donor chimerism, graft-versus-host disease and graft rejection have been observed.14-16 Thus, 130 
for those patients without suitable HSC donors and for those in critical health conditions, 131 
alternative treatment options beyond the standard of care are still required. The transplantation 132 
of autologous gene-modified cells is an alternative for the treatment of CGD, and has been 133 
implemented predominantly in X-CGD patients.17-20 These clinical trials have provided 134 
evidence that gene therapy can offer significant clinical benefit to CGD patients. However, 135 
most of the patients lacked significant long-term engraftment of transduced cells.21,22 136 
Although many factors may have influenced the engraftment potential of CD34+ cells during 137 
cell processing, alterations in numbers and/or fitness of HSCs in the CGD inflammatory 138 
background could also contribute to the engraftment deficit. We therefore analyzed the 139 
influence of chronic inflammation on the HSC compartment in X-CGD. We found a profound 140 
defect in HSC content and/or activity in the bone marrow (BM) of both X-CGD patients and 141 
mice.  142 
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The hematopoietic defects observed in X-CGD mice were mainly mediated by IL-1 and 143 
inhibition of IL-1 signaling suppressed HPC expansion in X-CGD mice but did not revert 144 
the functional defects in HSC activity.   145 
Thus, chronic inflammation in CGD leads to a dysregulated hematopoietic homeostasis. Our 146 
findings may not be limited to CGD, but may also be relevant to other pathologies with 147 
sustained chronic inflammation and autoinflammatory processes.23-27      148 
 149 
Methods  150 
Patient material  151 
BM and G-CSF mobilized peripheral blood (PB) mononuclear cells were obtained from X-152 
CGD patients (BM: n = 3, median 5.5 years old, range 0.7-8 years; PB: n=4, median: 10 years 153 
old, range 4-17 years) and healthy controls (BM: n = 4, median 11 years old, range: 3-14 154 
years; PB: n=4, median 29, range 25-37 years) after informed consent and approval by the 155 
local ethic committee.  156 
Mice  157 
B6.129S6-Cybbtm1Din/J (X-CGD mice, CD45.2), C57BL/6J (WT mice, CD45.2) and B6.SJL-158 
Ptprca Pepcb/BoyJ (CD45.1) mice were obtained from Charles River Laboratories (Sulzfeld, 159 
Germany). Health monitoring was conducted regularly by MFD Diagnostics (Wendelsheim, 160 
Germany) according to Federation for Laboratory Animal Science Associations guidelines. 161 
Animals with overt infections were not included in the study. Male littermates were used for 162 
experiments unless stated otherwise. B6.Cg MyD88tm1Aki mice (MyD88-deficient mice)28 163 
were bred at the Animal Facility of the German Cancer Research Center. Animal experiments 164 
were approved by the regional council (Regierungspräsidium Darmstadt, Germany). 165 
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Hematopoietic Stem Cell assays and Cytokine Arrays  166 
All assays including cell isolation, analysis and sorting, HSC assays, cell cycle analysis, 167 
cytokine stimulation experiments, lentiviral transductions, transplantation assays, competitive 168 
repopulation assays and cytokine arrays were done according to standard protocols. Detailed 169 
methods are provided in the Supplementary Material section in this article’s Online 170 
Repository. 171 
Statistical Analysis  172 
Statistical significances were calculated by unpaired two-tailed t-tests (Fig 1-2, 4A, C-D, F-G, 173 
5C), one-factorial ANOVA with Dunnet’s Multiple Comparison Test (Fig 4B), two-factorial 174 
ANOVA with Bonferroni posttests (Fig 3A, C, 4E, 5A-B) and three-factorial ANOVA (Fig 175 
4H). CRU frequency was calculated with L-Calc Limiting Dilution Analysis Software 176 
(StemSoft, Version 1.1). Overall test for differences in CRU frequencies between X-CGD and 177 
WT was performed with ELDA: Extreme Limiting Dilution Analysis 178 
(http://bioinf.wehi.edu.au/software/elda/index.html). Scatter plots indicate mean ± SD. Bar 179 
diagrams show mean + SD. * p < 0.05, ** p < 0.01, *** p < 0.001. 180 
Results 181 
Increased numbers of hematopoietic progenitors in X-CGD mice 182 
We analyzed the hematopoietic compartment of X-CGD mice and found significantly 183 
(p < 0.05-0.01) increased levels of LSK (Lin– Sca-1+ c-Kit+) cells, myeloid progenitors, 184 
common myeloid progenitors (CMPs) and granulocyte-monocyte progenitors (GMPs) in the 185 
BM, whereas the percentages of LSK SLAM (Lin– Sca-1+ c-Kit+ CD150+ CD48–), lineage 186 
negative (Lin–) and megakaryocyte-erythroid progenitors (MEPs) cells were unchanged (Fig 187 
1, A-E and see Fig E1, A-B, in the Online Repository and data not shown). BM cells from X-188 
CGD animals generated higher numbers of colonies derived from granulocyte-monocyte-189 
progenitors (CFU-GM) than cells from WT mice (see Fig E1, C, in the Online Repository). 190 
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LSK cells and the number of CFUs derived from spleen and PB were higher in X-CGD mice 191 
(Fig 1, F-G, and see Fig E1, D in the Online Repository). Cell cycle analysis revealed that the 192 
frequency of quiescent HSCs in X-CGD BM was significantly (p < 0.01) reduced compared 193 
to WT (Fig 1, H-I), suggesting an increase in the percentage of actively cycling HSCs in X-194 
CGD animals. 195 
 196 
Reduced numbers of HSCs in human X-CGD BM and mobilized peripheral blood 197 
We analyzed BM from X-CGD patients (n = 3) versus age-matched healthy controls (n = 4). 198 
We found a significant increase in the proportion of committed progenitors (CD34+ Lin–199 
 CD38+) in X-CGD BM at the expense of HSCs (CD34+ Lin– CD38–)(Fig 2, A-B and see Fig 200 
E2, A, in the Online Repository). Moreover, we found a shift in the balance of progenitors 201 
with the tendency towards less CMPs and MEPs and more GMPs in X-CGD BM when 202 
compared to healthy controls (Fig E2, B-D, in the Online Repository). Analysis of G-CSF 203 
mobilized PB mononuclear cells obtained from X-CGD patients (n = 3) revealed a 204 
pronounced reduction in the proportion of primitive HSCs (CD34+ CD38– CD90+) and early 205 
progenitors (CD34+ CD38–) compared to healthy donors (n = 3) (Fig 2, C-D and see Fig E3 in 206 
the Online Repository). Isolated PB CD34+CD38dimCD90+ cells from healthy donors and X-207 
CGD patients were cultured in the presence of early-acting cytokines for 4 days, thus 208 
resembling the conditions used in gene therapy settings. At day 4 HSCs and multipotent 209 
progenitors accounted for half of the population in the sample derived from healthy donors, 210 
while HSCs and MPPs derived from X-CGD patients were rapidly exhausted under these 211 
conditions (Fig 2, E). More than 85% of the X-CGD cells remaining in the culture were 212 
CD38+ late progenitors, a cell population with restricted engraftment capacities. These 213 
observations indicate that the alterations in the HSC/HPC pool observed in X-CGD mice are 214 
reciprocated in X-CGD patients and suggest a common underlying aetiology.           215 
 216 
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Impaired competitive repopulating ability of HSCs derived from X-CGD mice 217 
To assess the fitness of HSCs/HPCs we monitored the production of CFUs from BM long-218 
term cultures derived from X-CGD or WT animals after 4, 8 or 12 weeks of culture. Cells 219 
from X-CGD BM produced a significantly higher number of CFUs than WT cells after 220 
4 weeks of culture, consistent with the elevated LSK cell count (Fig 3, A). However, after 12 221 
weeks culture the number of X-CGD-derived CFUs was reduced compared to WT, indicating 222 
an accelerated exhaustion of the HSC pool. We also analyzed the self-renewal capability of 223 
HSCs in vivo by exposing mice to serial cytotoxic injury through repeated 5-fluorouracil (5-224 
FU) dosing. This treatment depletes replicating cells and promotes activation of formerly 225 
quiescent HSCs. In this assay, the survival of X-CGD mice was impaired compared to WT 226 
animals, again suggesting early exhaustion of HSCs (Fig 3, B).  227 
Next, we compared the capability of X-CGD and WT HSCs to reconstitute hematopoiesis in 228 
transplanted recipients. Lin– cells from either mouse group were differentially labeled using 229 
eGFP- or tBFP-encoding lentiviral vectors and equal numbers of gene-marked cells were 230 
mixed and transplanted into recipient mice. PB analyses at 2, 4, 8, 12 and 18 weeks showed 231 
that in the first weeks after transplantation, the frequency of gene-marked X-CGD cells in PB 232 
was higher compared to WT cells. However, gene-marked X-CGD cells were outcompeted by 233 
their WT counterparts from week 4 onwards, suggesting a lower frequency of long-term 234 
repopulating cells in the X-CGD samples (Fig 3, C). 235 
Lastly, we estimated the absolute number of cells with myeloid and lymphoid reconstitution 236 
potential in the BM of WT and X-CGD mice by a limiting dilution competitive repopulating 237 
unit (CRU) assay with LSK SLAM cells. Short-term repopulation analysis after 4 weeks 238 
resulted in similar CRU frequencies in both mouse groups. Upon 8 weeks and 16 weeks after 239 
transplantation X-CGD HSCs displayed a reduced (1.8-fold, p = 0.079) multilineage 240 
contribution to the PB of primary hosts compared to WT HSCs (Fig 3, D). Subsequently, 241 
isolated HSCs from animals transplanted with 50 and 250 LSK SLAM cells were used for 242 
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secondary BM transplantation. Sixteen weeks after secondary transplantation 79% (11/14) of 243 
the recipient animals injected with WT BM, but only 22% (4/18) of hosts receiving X-CGD 244 
BM showed successful multilineage repopulation in the PB (Fig 3, E). Taken together, our in 245 
vitro and in vivo experiments reveal a reduced potential of primitive HSCs derived from X-246 
CGD mice to reconstitute long-term hematopoiesis.  247 
 248 
No intrinsic defect in HSCs derived from X-CGD mice 249 
To study whether the defects observed for X-CGD HSCs were intrinsic or acquired over time, 250 
we analyzed fetal liver HSCs/HPCs. The composition of the fetal liver HSCs/HPCs was 251 
comparable for X-CGD and WT mice (see Fig E4, A, in the Online Repository). Competitive 252 
transplantations were performed with Lin– fetal liver cells from X-CGD and WT littermates. 253 
X-CGD fetal liver HSCs/HPCs were capable of engrafting and maintaining multilineage 254 
hematopoiesis to the same extent as WT cells (see Fig E4, B, in the Online Repository). This 255 
indicates that the observed deficits in long-term repopulation abilities of adult X-CGD HSCs 256 
are indeed acquired over time. As alterations in the BM microenvironment might be involved 257 
in the development of the long-term repopulation defect, we performed transplantations of 258 
WT (CD45.1) Lin– cells into WT (CD45.2) and X-CGD recipient mice. No significant 259 
differences in engraftment and chimerism, response to 5-FU challenge or hematopoietic 260 
reconstitution in secondary transplanted animals between both groups were observed (see Fig 261 
E4, C-E, in the Online Repository).  262 
 263 
Increased levels of proinflammatory cytokines in the BM of X-CGD animals 264 
In light of the established proinflammatory phenotype associated with CGD we screened BM 265 
fluid from WT and X-CGD mice for chemokine and cytokine levels using protein arrays. A 266 
high proportion of cytokines/chemokines (17/40) was significantly (p < 0.05) upregulated in 267 
the lavage from X-CGD BM (see Fig E5, A and Table E1 in the Online Repository). The 268 
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levels of C-X-C motif chemokine  (CXCL) 9, CXCL10, CXCL13, C-C motif chemokine 5 269 
(CCL5) and IL-1 were increased between 1.8 and 7.8-fold compared to WT. Likewise, the 270 
levels of other cytokines known to modulate HSC homeostasis were also altered (M-CSF, IL-271 
3, IL-1α, TIMP-1), although to a minor extend. Quantification of IL-1 by ELISA revealed a 272 
1.5-fold higher concentration in X-CGD compared to BM lavages from WT mice (Fig 4, A). 273 
Next we analyzed the effects of the cytokines and chemokines IL-1, CXCL10, CCL5 and 274 
CXCL9 on LSK cell proliferation in vitro. The stimulation of WT Lin– cells with CXCL10 275 
induced a modest increase in the frequency of LSK cells, while CCL5 and CXCL9 had no 276 
effect (see Fig E5, B, in the Online Repository). Addition of IL-1 was sufficient to expand 277 
the LSK cell pool 2.3- to 2.4-fold (Fig 4, B). Moreover, upon injection of IL-1 we observed 278 
a significant (p < 0.01) increase in the proportion of LSK cells in the BM of WT animals 279 
(Fig 4, C). This was associated with cell cycle activation of HSCs, as shown by increased 280 
BrdU incorporation into LSK CD150+ CD48– CD34– cells (Fig 4, D) and a decrease in the 281 
frequency of quiescent HSCs (Fig 4,  E).  282 
Most likely, the effects of IL-1 are mediated by IL-1binding to its receptor and subsequent 283 
activation of downstream signals, as the effects of IL-1 on HSC activation were absent in 284 
mice lacking MyD88, an essential adaptor molecule of IL-1 signaling (Fig 4, E). In addition, 285 
treatment of WT mice with IL-1 resulted in a higher content of colony forming cells in the 286 
bone marrow and increased LSK cell frequencies in the spleen, thus reproducing faithfully the 287 
phenotype observed in X-CGD animals (Fig 4, F-G). Lastly, we performed competitive 288 
transplantation assays with a mixture of bone marrow cells containing 2x106 mononuclear 289 
cells obtained from animals treated with IL1- and PBS. In all transplanted animals the 290 
engraftment of cells derived from the IL-1-treated animals was inferior to the engraftment of 291 
control cells (Fig 4, H). This data shows conclusively that IL-1 has detrimental effects on the 292 
fitness of the HSC pool.       293 
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Blocking inflammatory signals partially reverts the hematopoietic dysfunction in X-294 
CGD mice  295 
We treated 3-4 weeks old X-CGD and WT mice intraperitoneally with the IL-1 receptor 296 
antagonist Anakinra or PBS for 14-16 days. Anakinra treatment led to a decrease in the 297 
proportion of LSK cells in the BM (p < 0.05) and spleen of X-CGD but not WT mice and a 298 
decrease in the number of colony forming cells (CFCs) in peripheral blood (Fig 5, A-B, and 299 
see Fig E6 in the Online Repository). In addition, X-CGD mice were treated with the anti-300 
inflammatory steroid dexamethasone alone or in combination with Anakinra for 14 days. 301 
Dexamethasone and dexamethasone + Anakinra led to a decrease in the proportion of LSK 302 
cells in the BM (p < 0.05) and in the spleen of X-CGD mice, although the later did not reach 303 
significance (Fig 5, C-D). Also the number of CFCs in the bone marrow of dexamethasone-304 
treated animals was decreased (see Fig E6 in the Online Repository). The combined 305 
dexamethasone + Anakinra treatment reduced the IL-1 concentration in the bone lavages 306 
significantly (Fig 5, E). In competitive transplantation experiments 4,000 Lin– BM cells from 307 
PBS-, Anakinra-, or dexamethasone- treated X-CGD mice (CD45.2) were transplanted 308 
together with 105 CD45.1 mononuclear cells in CD45.1 recipients. Analysis of BM and PB 309 
chimerism at 19 and 8 weeks after transplantation, respectively showed a slight improvement 310 
in engraftment of cells derived from the Anakinra- or dexamethasone-treated animals, 311 
although the difference to the recipients of PBS-treated controls did not reach significance 312 
(see Fig E6 in the Online Repository). Nevertheless multilineage engraftment was obtained in 313 
8 out of 13 recipients transplanted with cells from the dexamethasone-treated group, while 314 
only 4 out of 10 recipients of the PBS-treated group showed tri-lineage engraftment above 315 
0.1%. 316 
  317 
 318 
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In summary our findings suggest that pro-inflammatory cytokines are responsible for the 319 
increased HPC pool and dysfunctional HSCs in X-CGD (Fig 5, F).  320 
 321 
Discussion  322 
Our data show that hematopoiesis is dysregulated in X-CGD. Both the quality and quantity of 323 
HSCs are affected, as demonstrated by the low proportion of primitive HSCs/HPCs present in 324 
BM cells from X-CGD patients and the low repopulation efficiency of murine X-CGD BM 325 
cells. Our observations add to the recent report by Panch et al., demonstrating a significant 326 
reduction in the number of G-CSF mobilized CD34+ cells in X-CGD patients.29 Similar to our 327 
findings, the deficit in CD34+ mobilization was directly associated with parameters linked to 328 
inflammation.          329 
Inflammation is known to promote HSC proliferation and orchestrates HSC/HPC egress to the 330 
blood stream via a variety of mechanisms.30-36 Inflammatory signals lead to augmented NF-331 
B activity, transcription of proinflammatory cytokines and activation of the inflammasome 332 
resulting in caspase-1-dependent secretion of the proinflammatory cytokines IL-1 and IL-333 
18.37-39 In CGD patients, increased activity of caspase-1 and elevated release of IL-1 and 334 
other proinflammatory cytokines by activated mononuclear cells contributes to dysregulated 335 
inflammatory responses, even in the absence of clinical infection.7-9,40-48 In view of the 336 
compelling evidence linking inflammation with defects in HSCs, it is not surprising that 337 
similar defects are observed in the HSC compartment of CGD patients and mice.  338 
We found that a series of proinflammatory mediators were upregulated in samples derived 339 
from BM of X-CGD animals partially overlapping with those previously identified in a cDNA 340 
microarray analysis on isolated X-CGD monocytes.49 In particular, we found increased IL-1 341 
levels in BM of X-CGD mice, a pleiotropic proinflammatory modulator of other cytokines, 342 
adhesion molecules and enzymes which also influences hematopoietic cell differentiation.50,51  343 
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IL-1 activates HSCs, which are known to express IL-1 receptors52 and induces HSCs to exit 344 
from quiescence. Cell cycle induction by IL-1 has been previously demonstrated in human 345 
CD34+ CD38– acute myeloid leukemia cells, leading to the downregulation of the cell cycle 346 
inhibitor p21, impaired self-renewal and reduced reconstitution potential.53 Similarly, reduced 347 
repopulation capacity has been shown for LSK cells upon treatment of mice with IL-1, 348 
which also triggers signaling through the IL-1 receptor.54  349 
We propose a model, in which a functional defect in X-CGD HSCs develops over time due to 350 
persistent exposure of HSCs/HPCs to inflammatory cytokines and chemokines. Chronic 351 
inflammation has been linked to enhanced cell cycle entry of HSCs, impaired repopulation 352 
ability and HSC exhaustion.35,36,55 Treatment of CGD patients with the IL-1 receptor 353 
antagonist Anakinra led to suppression of inflammation-related colitis in one study but only 354 
partial responses in others.41,46,56 In our studies, treatment of X-CGD mice with Anakinra 355 
alone resulted in reconstitution of HPCs levels and in combination with dexamethasone to a 356 
reduction of IL-1 secretion. Thus, proactive treatment of CGD patients with anti-357 
inflammatory drugs might therefore reduce chronic sterile inflammation in CGD and could 358 
also have an impact on the quantity of HSCs available for autologous gene therapy. In terms 359 
of clinical practice, our results implies that large numbers of CD34+ cells need to be collected 360 
for genetic modification from X-CGD patients undergoing gene therapy. Furthermore the 361 
decrease in the percentage of CD34+/CD38- in the peripheral blood of G-CSF-mobilized X-362 
CGD patients and the almost complete loss of primitive HSCs (CD34+CD38-CD90+ cells) 363 
after a 4 days culture period in the presence of cytokines raises concerns as to current 364 
expansion protocols and warrants the development of alternative mobilization and cell culture 365 
strategies to avoid premature cell differentiation and lastly graft failure. Finally, anti-366 
inflammatory treatment of X-CGD patients prior to collection of CD34+ cells might improve 367 
the ratio between HSCs and progenitors in the graft and consequently may increase the 368 
proportion of transduced cells with engrafting potential. Ultimately these measurements may 369 
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lead to successful engraftment of gene corrected cells in CGD patients enrolled in a gene 370 
therapy program.  371 
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Figure Legends 537 
FIG 1. Increased HPC pool and HSC activation in X-CGD mice.  538 
A-B, Number of LSK cells and FACS plots showing Lin– cells from the BM of WT and X-539 
CGD mice (n = 22). C-E, Frequency of myeloid progenitors, CMPs and GMPs in BM (n = 6). 540 
F, Colony formation by PB-derived cells (n = 18). G, Frequency of LSK cells in spleen 541 
(n = 9). H-I, Frequency of quiescent Ki67neg LSK SLAM cells from the BM and 542 
representative FACS plots showing the cell cycle distribution (n = 10). Error bars show mean 543 
± SD. *, p < 0.05; **, p < 0.01. 544 
 545 
FIG 2. X-CGD patients have fewer HSCs/HPCs in BM and PB. 546 
A-B, Frequency of Lin– CD34+CD38+/– cells in the BM of aged-matched healthy controls 547 
(HC, n = 4) and X-CGD patients (n = 3) and representative FACS plots. C-D, Frequency of 548 
CD34+CD38+/– cells and CD34+CD38–CD90+ HSCs in G-CSF-mobilized PB mononuclear 549 
cells (n = 4). E, Representative FACS plots showing the distribution of HSCs/HPCs after 4 550 
days culture of sorted PB CD34+CD38dimCD90+ cells from one HC and two X-CGD patients. 551 
Error bars show mean + SD. *, p < 0.05. 552 
 553 
FIG 3. HSCs/HPCs from X-CGD mice show faster exhaustion during hematopoietic 554 
reconstitution than WT cells.  555 
A, Colony formation by BM cells after long-term culture (n ≥ 9). B, Kaplan-Meier survival 556 
curves after serial 5-FU challenge (n = 6). C, Proportion of eGFP+ and tBFP+ donor-derived 557 
PB cells two to 18 weeks after competitive transplantation of gene-marked WT and X-CGD 558 
cells (n = 6). D, CRU assays with sorted HSCs. Shown is the frequency ± SE (n = 3). E, 559 
Percentage of multilineage reconstituted mice transplanted with BM cells obtained from D 560 
(n ≥ 14). Data are provided as mean + SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 561 
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FIG 4. IL-1 is increased in the BM of X-CGD mice and induces HSC activation, HPC 562 
expansion and reduces HSC long-term engraftment. 563 
A, IL-1 protein levels in bone lavages (n = 13). B, LSK cell frequency of IL-1-treated WT 564 
Lin– cells (n = 6). C-D, Frequency of LSK cells and BrdU incorporation in LSK SLAM 565 
CD34– cells in the BM of WT mice after IL-1 or PBS treatment (C: n = 7; D: n = 3). E, Cell 566 
cycle distribution of LSK SLAM CD34– cells in IL-1-treated WT and MyD88-deficient 567 
mice (n = 3). F-G, Frequency of BM-derived CFUs and spleen LSK cells in IL-1-treated 568 
WT mice (n = 3). H, PB chimerism 16 weeks after competitive transplantation of cells from 569 
IL-1 or PBS-treated animals (n = 4). Error bars show mean ± SD. *, p < 0.05; **, p < 0.01; 570 
***, p < 0.001. 571 
 572 
FIG 5. Blocking inflammatory signals restores HPC levels in X-CGD mice. 573 
A-B, Frequency of LSK cells in the BM (A) and spleen (B) of WT and X-CGD mice after 574 
treatment with PBS or Anakinra (n = 3-4). C-D, Frequency of LSK cells in the BM (C) and 575 
spleen (D) of X-CGD mice after treatment with PBS or Dexamethasone +/- Anakinra (n = 4). 576 
E, IL-1b concentration in bone lavages from the mice in (C-D). Error bars show mean ± SD. 577 
*, p < 0.05; **, p < 0.01. D, Proposed model of HSC/HPC exhaustion in X-CGD BM.  578 
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Cytokine / chemokine Fold change 
X-CGD 
WT 
P-value*  
CXCL9 7.8 0.046 
CCL5 3.9 0.009 
CXCL10 3.3 0.018 
CXCL13 2.7 0.002 
IL-1Ra 1.8 0.004 
IL-1 1.8 0.000 
TREM-1 1.7 0.005 
CCL2 1.6 0.000 
CCL3 1.5 0.013 
M-CSF 1.3 0.005 
IL-3 1.2 0.039 
TIMP-1 1.2 0.001 
IL-1 1.2 0.019 
CXCL2 1.1 0.016 
CCL4 1.1 0.001 
IL-6 1.1 0.013 
IL-5 1.1 0.030 
 
TABLE E1. Increased cytokine and chemokine levels in bone marrow fluid from X-CGD mice  
compared to WT controls as determined by protein arrays. 
*P values from unpaired two-tailed t-tests. 
Repository E Figures No.E1-E5
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FIG E1. Analysis of the hematopoietic compartment in X-CGD and WT mice. A, Gating strategy used to 
identify HPC subpopulations in the bone marrow. B, Markers for myeloid progenitors, common myeloid 
progenitors (CMP), megakaryocyte-erythroid progenitors (MEP) and granulocyte-monocyte progenitors (GMPs) 
according to Challen et al., Cytometry A. 2009 Jan; 75(1):14-24. C, Number of CFU-GM in bone marrow 
samples from WT and X-CGD animals (n = 8). D, Frequency of LSK cells in peripheral blood of WT and X-
CGD animals (n = 8). Statistical significance was calculated by unpaired two-tailed t-test. 
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FIG E2. X-CGD patients have fewer HSCs/HPCs (CD38– CD34+ Lin– cells) in the bone marrow and
the distribution of CD38+ CD34+ Lin– committed progenitor cells differs from healthy controls. A,
Representative FACS plots from bone marrow of a healthy donor and an aged-matched X-CGD patient
showing the gating strategy to identify CMPs, GMPs and MEPs. HSCs/HPCs are within the CD38– CD34+
Lin– population (gate not shown), while committed progenitors (CD38+ CD34+ Lin– cells) can be further
separated into CMPs (CD38+ CD34+ Lin– CD123+ CD45RA–), GMPs (CD38+ CD34+ Lin– CD123+
CD45RA+) and MEPs (CD38+ CD34+ Lin– C123– CD45RA–). B-D, Frequency of CMPs, GMPs and MEPs
within the committed progenitor cell population in the bone marrow of X-CGD patients (n = 3) and age-
matched healthy controls (HC) (n = 4) as determined by flow cytometry.
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FIG E3. X-CGD patients contain less CD34+ CD38– HSCs/HPCs in the peripheral blood 
(PB) upon apheresis than healthy controls. A, Representative FACS plots of G-CSF-mobilized 
PB mononuclear cells obtained from a healthy control (HC) and an X-CGD patient.  HSCs are 
defined as CD34+ CD38– CD90+ cells. 
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FIG E4. HSCs/HPCs from X-CGD fetal liver at E15.5 are present at the same frequencies and have the 
same reconstitution capacity as WT cells. A, Frequency of CD11b+ Lin–, CD11b+ LSK and CD11b+ LSK 
SLAM cells in the fetal liver of WT and X-CGD mice (n ≥ 17). B, Competitive repopulation experiment using 
Lin– fetal liver cells from WT and X-CGD mice. The graphic shows exemplarily the result of PB reconstitution 
at week 16 after transplantation. C-E, X-CGD stromal cells are not impaired in their capability to support HSC 
functions. C, Survival of 5-FU-treated X-CGD or WT mice transplanted with WT (CD45.1) mononuclear cells 
(n = 7). D, Donor (CD45.1) chimerism in PB of transplanted WT and X-CGD mice 16 weeks after 
transplantation (n ≥ 11). E, Kaplan-Meier survival curves of secondary hosts transplanted with mononuclear 
cells derived from the animals shown in 4D (n = 20). Error bars show SD. 
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FIG E5. Cytokine levels are increased in bone lavages from X-CGD compared to WT mice and CXCL10 
increases LSK cell frequency in vitro. A, Representative cytokine array using bone lavages from WT and X-
CGD mice. Gray frames indicate significant differences (p < 0.05) between the littermate samples, black frames 
show cytokines upregulated ≥ 1.5-fold in X-CGD compared to WT lavages. Examination of the mice did not 
reveal any overt infections linked to these results. No differences in white blood counts (16.0 x 103/µl ± 1.2 vs. 
14.0 x 103/µl ± 1.3), PB lymphocyte counts (11.8 x 103/µl ± 1.0 vs. 9.7 x 103/µl ± 0.5), or mean spleen weight 
(107 ± 5 mg vs. 110 ± 16 mg) were found for the WT versus X-CGD mice used for this analysis, respectively. B, 
LSK cell frequency of WT Lin– cell after 3 days of culture with 250 ng/ml CXCL10, CCL5 or CXCL9 (n = 3). 
Statistical significance was analyzed by one-factorial ANOVA with Dunnet’s Multiple Comparison Test. Error 
bars show mean ± SD. *, p < 0.05 
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FIG E6. Blocking IL-1 signaling reduces the number of colony forming cells in bone 
marrow and peripheral blood, but has only minor effects on HSC engraftment.
A, WT and X-CGD mice were injected intraperitoneally with PBS or Anakinra (25 µg/g body 
weight) twice a day for 14-16 days and the frequency of colony-forming cells was measured in 
the peripheral blood (PB). B, Bone marrow (BM) chimerism in CD45.1 mice 19 weeks after 
transplantation of 4,000 Lin– BM cells obtained from PBS- or Anakinra-treated X-CGD mice 
(CD45.2) together with 105 CD45.1 mononuclear competitor cells (n = 3). C-D, X-CGD mice 
were treated with Dexamethasone (Dex, 2 µg/g body weight) or PBS daily for 14 days. C, BM 
cells were assayed for the frequency of colony-forming units (CFUs) (n = 3). D, Lin– BM cells 
from treated donors were used for competitive transplantation as described in (B). PB 
chimerism is depicted 8 weeks after transplantation (n ≥ 10). Only animals with tri-lineage 
engraftment above 0.1% are shown. Error bars show mean ± SD.
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Methods  
 
Cell Isolation, Flow Cytometry and Cell Sorting.  
For isolation of BM cells from mice humeri, tibiae, femurs and hips were dissected and 
flushed with PBS. Lineage depletion was performed with Lineage Cell Depletion Kit 
(MiltenyiBiotec, BergischGladbach, Germany) or Easy Sep Biotin Selection Kit (StemCell 
Technologies, Köln, Germany).For isolation of fetal liver HSCs the livers were dissected at 
E15.5 and triturated to single cell suspension. After genotyping, cells were incubated with 
biotinylated antibodies against CD3, CD19, B220, CD41, Gr-1 and Ter119 and lineage 
depleted like BM samples.  
PB from tail vein was collected in EDTA tubes, underwent erythrocyte lysis (Pharm Lyse 
buffer, BD Biosciences, Heidelberg, Germany) and staining for flow cytometry. Spleen 
samples were prepared by mincing the organ through a cell strainer and erythrocyte lysis as 
described for PB. 
For isolation of human CD34
+
 cells we used the Lineage Cell Depletion Kit (MiltenyiBiotec) 
as recommended by the manufacturer. Aliquots were kept frozen in CryoStore freezing 
medium (StemCell Technologies) until use or analyzed immediately after isolation. Cells 
were analyzed and sorted on a FACSCanto II, LSR Fortessa and FACSAria (all: BD 
Biosciences) using the following antibodies: CD3 (500A2), human CD90 (5E10), human 
CD123 (7G3) (all: BD Biosciences), CD11b (M1/70), CD19 (eBio1D3), CD34 (RAM34), 
human CD34 (4H11), human CD38 (HIT2), CD41 (eBioMWReg30), CD45.1 (A20), human 
CD45RA (HI100), CD48 (HM48-1), CD127 (A7R34), B220 (RA3-6B2), c-Kit (2B8), Gr-1 
(RB6-8C5), Sca-1 (D7), Ter-119 (all: eBioscience, Frankfurt, Germany), CD16/32 (93), 
Repository - Suppl. Materials Revision 2s 
CD45.2 (104), CD150 (TC15-12F12.2) (all: BioLegend, Fell, Germany). Streptavidin 
eFluor450 was obtained from eBioscience. FACSDiva and FlowJo software were used for 
analysis.  
 
Cell Cycle Analysis.  
Ki67-FITC (clone B56) intracellular staining was performed according to BD Biosciences 
protocols, then cells were treated with RNase A (60 µg/ml) and stained with 0.5 µM TO-
PRO-3 (both: Life Technologies, Darmstadt, Germany) or Hoechst33342 (Molecular Probes, 
Darmstadt, Germany). For IL-1 stimulation and in vivoBrdU-labeling mice received 2.5 µg 
IL-1 or PBS 20 h before BM harvest followed by BrdUintraperitoneally (18 mg/kg) 14 h 
before analysis. BrdU incorporation was detected using the FITC BrdU Flow Kit (BD 
Biosciences). 
 
Colony Formation Assays.  
CFU and long-term culture assays were performed according to the manufacturer’s protocols 
using MethoCult GF M3434 and MyeloCult M5300 (both: StemCell Technologies). 
 
5-FU Treatment of mice.  
Weight-matched WT and X-CGD littermates or mice from WT (CD45.1) transplantations in 
WT (CD45.2) or X-CGD mice were injected weekly with 150 µg/g 5-fluorouracil (5-FU, 
Sigma-Aldrich, Taufkirchen, Germany). Neomycin (1.67 mg/ml) was added to drinking 
water. Mice were monitored and sacrificed in case of > 20% loss of body weight. Survival 
rates of the littermates were recorded. 
 Lentiviral Transduction.  
Lentiviral vectors encoding for eGFP and tBFP were kindly provided by Christian Brendel, 
Georg-Speyer-Haus, Frankfurt. Vectors were produced as previously 
described.
E1
Transduction was performed as in Brendel et al.
E2
, but cells were 
prestimulatedwith 300 ng/ml mSCF, 300 ng/ml mTPO, 100 ng/ml mFlt3-Ligand, 60 ng/ml 
mIL-3. 
 
Transplantation of murine cells.  
Lethally irradiated (9.5 Gy) mice were transplanted via tail vein injections. Unless stated 
otherwise, cells were transplanted into WT (CD45.1) mice. For CRU assays 2, 10, 50 or 250 
sorted LSK SLAM cells were transplanted with 10
5
 competitor mononuclear cells (MNCs) 
from WT (CD45.1) mice. PB of transplanted recipients was analyzed after 16 weeks by flow 
cytometry and mice with ≥ 1% donor-derived cells in the T-, B- and myeloid cell 
compartment were scored positive for donor cell engraftment. CRU frequency was calculated 
with the L-Calc software (Stem Cell Technologies). For secondary transplants, 10
5
 BM 
MNCs from the first recipients transplanted with 50 or 250 LSK SLAM cells were 
transplanted with an equal number of WT (CD45.1) MNCs. Criteria for reconstitution were 
the same as above. For fetal liver experiments, 10
4
 Lin
–
 fetal liver cells and 2 x 10
5
 adult WT 
(CD45.1) MNCs were transplanted into irradiated WT (CD45.1) recipient mice.WT and X-
CGD Lin
–
 fetal liver cells were obtained from littermate pairs. For assays with gene-marked 
cells, Lin
–
 cells from WT or X-CGD animals were transduced and 1:1 mixtures of transduced 
cells containing 70%-90% eGFP and tBFP-expressing cells were transplanted. For analysis of 
stromal cell effects, MNCs from WT (CD45.1) mice were transplanted into WT or X-CGD 
recipient mice. For 5-FU treatment, 5 x 10
5
 WT (CD45.1) BM MNCs were injected and 
treatment was initiated 8 weeks after bone marrow transplantation (BMT). For serial BMTs 
2 x 10
5
 WT (CD45.1) BM MNCs were transplanted. After 16 weeks 2 x 10
5
 BM MNCs from 
the first recipients were transplanted into secondary WT or X-CGD hosts. Survival rates of 
secondary recipients were monitored as during 5-FU treatment. 
 
Cytokine Arrays and IL-1 ELISA.  
BM lavage was obtained by flushing the hind limbs of WT and X-CGD mice with 0.5 ml 
PBS. Cells were removed by centrifugation and the lavage was frozen in aliquots at -80°C. 
BM lavage (0.35 ml) was used for the Proteome Profiler Mouse Cytokine Array Panel A 
(R&D Systems, Wiesbaden-Nordenstadt, Germany) according to the manufacturer’s 
instructions and detected with the Odyssey Infrared Imaging System using IRDye 800CW 
Streptavidin. Signal quantification was performed with the Odyssey Application Software 
2.1.12. Bone lavage samples were also analyzed with the RayBio Mouse IL-1 ELISA Kit 
(RayBiotech, Norcross, GA, USA) according to the manual.  
 
Cytokine stimulation experiments  
Sorted PB CD34
+
, CD38
dim 
and CD90
+
 cells (500.000 cells/ml) were cultured in X-VIVO20 
(Lonza, Walkersville, MD, USA), 1% HSA, hIL3 20ng/ml, hTPO 100ng/ml, hFlt-3L 
300ng/ml, hSCF 300ng/ml for 4 days.  
For the murine in vitro experiments 10
5
 Lin
–
 cells were cultured in StemSpanSFEM 
(StemCell Technologies) + TPO + SCF (both 100 ng/ml), antibiotics and 75 ng/ml or 
250 ng/ml IL-1 or 250 ng/ml CCL5, CXCL9 or CXCL10 (all: murine cytokines; PeproTech, 
Rocky Hill, NJ, US) or PBS. LSK cell frequency was determined after 3 days by FACS. For 
the in vivo experiments 250 ng IL-1(LSK cells in BM, CFUs) or 2.5 µg IL-1 were injected 
into WT mice 12 h (LSK cells in BM, CFUs), 20 h (BrdU labeling and cell cycle analysis) or 
44 h (LSK cells in spleen) prior to sacrifice. To analyze the effects of IL-1 treatment in vivo 
on the engraftment capacity of HSCs upon transplantation, CD45.1 and CD45.2 WT mice 
were injected intraperitoneally with 250 ng IL-1 or PBS 5x every other day. Subsequently, 
MNCs were isolated and 2 x 10
6
 MNCs from differently treated mice with distinguishable 
CD45 markers were mixedand transplanted into both CD45.1 and CD45.2 recipients. PB 
chimerism was analyzed 16 weeks after transplantation.  
 
Anakinra and Dexamethasone treatment of mice  
Anakinra (Kineret, SOBI, Stockholm, Sweden) treatment of X-CGD and WT mice consisted 
of two intraperitoneal injections per day at a concentration of 25 µg/g body weight for 14-16 
days. Dexamethasone (Sigma-Aldrich) with/without Anakinra treatment of X-CGD mice was 
performed by daily intraperitoneal injections of 2 µg/g body weight Dexamethasone +/- 
10 µg/g body weight Anakinra for 14 days. For subsequent BM transplantation, Lin
–
 cells 
were isolated from treated X-CGD mice and transplanted together with CD45.1 MNCs as 
competitors into CD45.1 WT recipients (4000 Lin
–
 cells + 10
5
 MNCs per mouse). BM 
chimerism was detected 19 weeks after transplantation. 
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